Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premiumMarket Watch • 11/15/23
Compared to Estimates, Gilead (GILD) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/08/23
Gilead Squashes Expectations On The Back Of A Bullish Move For Its Cancer DrugsInvestors Business Daily • 11/07/23
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI CancersBusiness Wire • 11/06/23
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI CancersBusiness Wire • 11/06/23
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & MoreZacks Investment Research • 11/06/23
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023Business Wire • 11/03/23
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023Business Wire • 11/02/23